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Abstract word count: 248 5 
Abstract 6 
Background: Studies using administrative data commonly rely on diagnosis codes to identify 7 
venous thromboembolism (VTE) events. Our objective was to assess the validity of using 8 
International Classification of Disease, 9th Revision (ICD-9) codes in identifying recurrent VTE. 9 
Materials and Methods: Among 5497 adults with confirmed incident VTE from four healthcare 10 
delivery systems in the Cardiovascular Research Network (CVRN), we identified all subsequent 11 
inpatient, emergency department (ED), and ambulatory clinical encounters associated with an 12 
ICD-9 code for VTE (combined with relevant radiology procedure codes for inpatient/ED VTE 13 
codes in the secondary discharge position or outpatient codes) during the follow-up period. 14 
Medical records were reviewed using standardized diagnostic criteria to assess for the presence 15 
of new, recurrent VTE. The positive predictive value (PPV) of codes was calculated as the 16 
number of valid events divided by total encounters.  17 
Results: We identified 2397 encounters that were considered potential recurrent VTE by ICD-9 18 
codes. However, only 31.1% (95%CI: 29.3-33.0%) of encounters were verified by reviewers as 19 
true recurrent VTE. Hospital or ED encounters with VTE codes in the primary position were 20 
more likely to represent valid recurrent VTE (PPV 61.3%, 95%CI: 56.7-66.3%) than codes in 21 
secondary positions (PPV 35.4%, 95%CI: 31.9-39.3%), or outpatient codes (PPV 20.3%, 95%CI: 22 
 6 
18.3-22.5%). PPV was low for all VTE types (29.9% for pulmonary embolism, 38.3% for lower 1 
and 37.7% for upper extremity deep venous thrombosis, and 14.1% for other VTE).  2 
Conclusions: ICD-9 codes do not accurately identify new VTE events in patients with a prior 3 
history of VTE.  4 
 5 
Keywords: venous thromboembolism; pulmonary embolism; deep vein thrombosis; electronic 6 
health record; International Classification of Diseases, 9th Revision 7 
 8 
Abbreviations: CI, confidence interval; CPT, using current procedural terminology; CVRN VTE, 9 
Cardiovascular Research Network Venous Thromboembolism; ICD-9, International Classification 10 
of Diseases, 9th Revision; KPCO, Kaiser Permanente Colorado; KPNC, Kaiser Permanente 11 
Northern California; MC, Marshfield Clinic; PPV, positive predictive value; SD, standard 12 
deviation; VTE, venous thromboembolism.  13 
 7 
Introduction 1 
Venous thromboembolism (VTE) (i.e., deep venous thrombosis or pulmonary embolism) 2 
has an estimated annual incidence of 900,000 events in the U.S.[1, 2] VTE poses a substantial 3 
clinical and economic burden to individuals and society, not only because of the high morbidity, 4 
mortality, and costs associated with the initial event, but also because of the risk of recurrent 5 
VTE events.[1-3] Recognition of the urgent need to optimize treatment and outcomes of VTE by 6 
the Center for Medicaid and Medicare Services, the Agency for Healthcare Research and 7 
Quality, and the Surgeon General,[2, 4, 5] has led to efforts to widespread collection of VTE-8 
related data for quality improvement and outcomes research.  9 
Administrative databases are increasingly used for potential quality surveillance as well 10 
as pharmacoepidemiologic and outcomes research due to multiple advantages, including their 11 
widespread availability, large population coverage, reflection of “real world” practice, lower 12 
research-related costs, and longer observation periods than prospective cohort studies of 13 
selected participants.[6] However, administrative databases have relied on coded diagnoses 14 
such as International Classification of Disease, 9th Revision (ICD-9) diagnosis codes with 15 
questionable validity for many health conditions.[6, 7] Even with the introduction of ICD-10 16 
codes, which have enhanced granularity over older codes,[8] ICD-9 codes are still frequently 17 
used to identify disease conditions prior to the widespread use of ICD-10 codes and important 18 
in retrospective studies.[9-11] Prior research investigating the accuracy of VTE diagnosis codes 19 
have primarily focused on incident VTE events or have not separated out incident from 20 
prevalent events. This research has yielded widely varying results depending on the included 21 
population, with positive predictive values (PPV) as low as 26% to 31% in outpatients.[7, 12, 13] 22 
 8 
Very little attention has been given to assessment of the validity of administrative codes to 1 
identify new VTE events in patients with a prior history of VTE (e.g., recurrent VTE events), even 2 
though recurrent VTE is one of the most important outcome measures in VTE research.  3 
Understanding the accuracy of administrative codes to identify recurrent VTE is 4 
important to determine their utility for use in research, quality improvement efforts for 5 
secondary VTE prophylaxis, and policy-making. Therefore, we assessed the validity of ICD-9 6 
codes for identifying recurrent VTE events against standardized criteria using medical records in 7 
a diverse, multi-institutional, community-based population of adults with previous VTE. 8 
 9 
Material and Methods 10 
Setting and Population 11 
The Cardiovascular Research Network Venous Thromboembolism (CVRN VTE) Study 12 
included adults with VTE from four integrated healthcare delivery systems in the U.S. (Kaiser 13 
Permanente Northern California [KPNC], Kaiser Permanente Colorado [KPCO], Marshfield Clinic 14 
[MC], and Geisinger Health System), reflecting a diverse population in the corresponding 15 
geographic areas of Northern California, the Denver metropolitan area in Colorado, central and 16 
northwest Wisconsin, and central and northeast Pennsylvania, respectively. This study was 17 
considered exempt according to the updated Common Rule for Human Research.[14]  18 
Details of the CVRN VTE study have been previously published.[13, 15] Briefly, health 19 
plan members aged ≥21 years with a confirmed incident VTE event from October 1, 2004 to 20 
December 31, 2010 and who had at least 12 months of continuous health plan membership 21 
with pharmacy benefits before the index VTE event were included in the study. To restrict the 22 
sample to patients with a first VTE event, the index VTE diagnosis was defined as the first 23 
 9 
medical encounter with a diagnosis code for VTE. Patients with a VTE diagnosis code or a 1 
prescription of anticoagulants within four years before the index event were excluded. VTE 2 
diagnoses were identified from electronic medical records and based on ICD-9 codes for 3 
pulmonary embolism (415.1x), deep venous thrombosis of the lower extremities (451.1x, 451.2, 4 
451.81, 453.4x, 453.5x), upper extremities (451.83, 451.84, 451.89, 453.72, 453.73, 453.74, 5 
453.75, 453.76, 453.77, 453.82, 453.83, 453.84, 453.85, 453.86, 453.87) or other venous 6 
thrombosis (451, 451.9, 452, 453, 453.0, 453.1, 453.2, 453.3, 453.79, 453.8, 453.89, 453.9). ICD-7 
9 codes were used during the entire period of the study. We did not include diagnosis codes for 8 
superficial thrombophlebitis or pregnancy-related VTE. Any inpatient or emergency department 9 
encounter with a relevant ICD-9 diagnosis code in the primary or secondary position as well as 10 
outpatient encounters were included. All administratively coded VTE events underwent chart 11 
review by trained physician and pharmacist chart abstractors using standardized criteria for 12 
validation and collection of additional information that were not otherwise available from 13 
administrative data. The final CVRN VTE study population consisted of 5,497 patients with a 14 
valid first time incident VTE event. 15 
Identification and Validation of Recurrent VTE Events 16 
 We considered a valid recurrent VTE diagnosis to be a confirmed new pulmonary 17 
embolism or deep venous thrombosis (lower or upper extremity) occurring at the same or new 18 
site. To identify possible recurrent VTE events, we searched electronic medical records for all 19 
healthcare encounters with an ICD-9 diagnosis code for pulmonary embolism, deep venous 20 
thrombosis of the lower and upper extremities, or other venous thrombosis (e.g. hepatic vein, 21 
inferior vena cava, see Appendix Table A.1) subsequent to the initial VTE discharge. Follow-up 22 
 10 
for recurrent VTE events occurred until death, disenrollment from the health system or end of 1 
administrative follow-up on December 31, 2013. Individual patients could have more than one 2 
recurrent VTE event. We included inpatient, emergency department, and outpatient 3 
encounters using the same set of ICD-9 VTE codes used for identifying incident VTE. For 4 
inpatient and emergency department encounters, relevant codes in the primary or secondary 5 
position were considered. Inpatient/emergency encounters with codes in the secondary 6 
discharge position and outpatient encounters were considered if there was a relevant radiology 7 
code present within 7 days of the diagnosis (i.e. up to 7 days prior and up to 7 days after). 8 
Relevant radiology procedure codes were identified using current procedural terminology (CPT) 9 
codes for ultrasound examinations of the extremity veins, inferior vena cava, or pelvic vessels, 10 
CPT codes for ventilation-perfusion scan of the lung, or CPT codes for computed tomography of 11 
the chest with contrast (Appendix Table A.2). 12 
Medical records of all possible recurrent VTE events were manually reviewed at 3 of the 13 
4 medical sites (KPCO, MC, Geisinger) by trained chart abstractors for validation. For the fourth 14 
site (KPNC), we used a combination of manual chart review and automated text processing (i.e., 15 
natural language processing) to verify whether events were valid recurrent VTE due to the large 16 
number of possible events.  This automated text process scanned the unstructured electronic 17 
note text for mentions of recurrent VTE preceded or followed by a negation term using a 18 
clinical negation ontology to identify encounters that were considered “definitely not VTE,” and 19 
these events were categorized as “invalid” VTE events. Trained physician and pharmacist 20 
reviewers using structured data forms manually reviewed encounters assessed by the 21 
automated text processing method as “possible VTE” or “likely to be VTE.”  22 
 11 
The chart review process was similar to that used in our previously described study of 1 
incident VTE events.[13] All available hospital admission, transfer and discharge records, 2 
emergency department and outpatient notes, and radiology reports within 72 hours before and 3 
after the recurrent VTE encounter were obtained and reviewed by trained reviewers. A 4 
standardized data abstraction form was used to identify valid recurrent VTE events. We 5 
determined a recurrent VTE event to be valid if there was evidence of an acute VTE event in 6 
radiology, operative, or autopsy records or as described by physician notes. If the presentation 7 
and management described in the current encounter represented a continuation of a prior 8 
episode of VTE, we did not consider the event to be valid unless there was new 9 
symptomatology, extension or progression of prior thrombus, or VTE in a new location.[16, 17] 10 
For encounters that were not considered valid recurrent VTE events, reviewers were required 11 
to indicate the reason why they were considered invalid. 12 
Patient Characteristics 13 
Characteristics of eligible patients were obtained from clinical and administrative 14 
databases using extracted data standardized to a Virtual Data Warehouse.[18] We also 15 
searched health plan pharmacy databases for filled anticoagulant medication prescriptions 16 
(warfarin, low molecular weight heparin, and fondaparinux) within 7 days of the possible 17 
recurrent VTE event. We did not include direct oral anticoagulants, because they had not been 18 
approved in the U.S. for treatment of acute VTE during the study period.  19 
Statistical Analysis 20 
All analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC). 21 
 12 
The primary outcome was the PPV of ICD-9 codes suggesting recurrent VTE events compared to 1 
manual review of medical records. PPV was calculated as the number of chart-validated VTE 2 
events divided by the total number of events identified by ICD-9 codes with associated 95% 3 
confidence intervals. We investigated whether the PPV for recurrent VTE differed by type of 4 
VTE (i.e. pulmonary embolism, lower extremity deep venous thrombosis, upper extremity deep 5 
venous thrombosis, and other VTE), and by each individual ICD-9 code identifying any VTE event 6 
(see above). To investigate whether we could find a specific set of characteristics that can 7 
improve PPV, we also assessed whether the PPV for recurrent VTE varied depending on the 8 
discharge position of the diagnosis code (primary compared to secondary position) or 9 
encounter setting (inpatient or emergency department encounters compared to outpatient 10 
encounters). We also assessed whether recurrent VTE events could be more accurately 11 
identified if we used a combination of ICD-9 diagnosis codes with a filled prescription for 12 
anticoagulants within 7 days of the possible recurrent VTE encounter in patients that had not 13 
filled an anticoagulant prescription for at least 6 months prior to the date of the possible 14 
recurrent VTE event.  15 
Because the first recurrent VTE event is most relevant for pharmacoepidemiologic 16 
studies, we conducted a sensitivity analysis restricting to the first encounter that met criteria 17 
during follow-up to assess whether this would improve the accuracy of identifying recurrent 18 
VTE. In a second sensitivity analysis, we implemented a lag period by excluding potential 19 
recurrent VTE events that occurred within 7 days of the incident event, as they could represent 20 




The CVRN VTE cohort included 5,497 adults who had confirmed acute incident VTE, with  2 
mean (SD) age of the cohort 65.7 (15.8) years, 51.4% women and 79.6% of white race. During 3 
the follow-up period, 2,397 eligible clinical encounters from 1,592 unique patients were 4 
assigned an ICD-9 code for VTE that represented potential acute recurrent VTE events (only 5 
considering inpatient/emergency department codes in the secondary position or outpatient 6 
codes if a relevant radiology procedure code was present within 7 days). Sixty-nine percent of 7 
patients had just one clinical encounter with a VTE code in the follow-up period, while 19.7% 8 
had 2, 6.3% had 3, and the remaining 5.1% had 4 or more. There were slightly more qualifying 9 
ambulatory encounters than inpatient/emergency department visits (Table 1) and most 10 
encounter codes were for pulmonary embolism (41.1%) or isolated lower extremity deep 11 
venous thrombosis (40.7%).  12 
Predictive Value of ICD-9 Diagnosis Codes to Identify Recurrent Venous Thromboembolism 13 
 Among the 2,397 encounters with a diagnosis of VTE, 1,390 were first assessed using 14 
automated text processing, and 615 were identified as clearly invalid encounters and did not 15 
undergo further chart review validation. The remaining 1,782 medical records were manually 16 
reviewed. Overall, 746 encounters were identified as valid acute VTE events, for an overall PPV 17 
of 31.1% (95% CI: 29.3-33.0%) (Table 2). The PPV differed by type of VTE event, encounter 18 
setting, and whether the diagnosis code was in the primary or secondary discharge position. 19 
VTE codes from the ambulatory care setting represented acute new VTE in only 20.3% (95% CI: 20 
18.3-22.5%) of encounters. Secondary diagnosis codes from the hospital/emergency 21 
department setting were marginally better at 35.4% (95% CI: 31.9-39.3%). For patients in the 22 
 14 
hospital/emergency department setting, PPV for pulmonary embolism codes in the primary 1 
position was 67.0% (95% CI: 61.0-73.6%). PPVs for VTE codes of other sites were significantly 2 
lower (Table 2). The PPV associated with individual VTE codes are presented in the 3 
Supplemental Table.  4 
In all, 596 VTE encounters were from patients who had not been prescribed 5 
anticoagulants in the prior 6 months and then had a new prescription for anticoagulant within 7 6 
days of the clinical encounter. Incorporating anticoagulant prescription increased PPV to 54.2% 7 
(Table 3). VTE codes for pulmonary embolism, or of the upper or lower extremities, were 8 
reasonably accurate in the hospital/emergency department setting when coupled with 9 
anticoagulant prescription data if the diagnosis codes were in the primary position, or when 10 
considering codes in both primary and secondary positions combined (PPV 67.1% for any VTE, 11 
73.2% for pulmonary embolism, and 67.6% for lower extremity deep venous thrombosis; 12 
results not shown). Ambulatory codes continued to be poorly predictive of actual recurrent VTE 13 
events even when incorporating new anticoagulant dispensing data (Table 3).  14 
In a sensitivity analysis restricting to the 1592 first encounters with a potential recurrent 15 
VTE event, the results remained similar: the overall PPV to identify any recurrent VTE event 16 
only slightly increased to 33.7% (Appendix Table A.3). The exclusion of potential recurrent VTE 17 
events that occurred within 7 days of the incident event using a second sensitivity analysis did 18 
not substantially change the results (Appendix Table A.4). 19 
For the 1,036 clinical encounters that underwent manual chart review and that did not 20 
represent valid recurrent VTE, reviewers attempted to ascertain the reasons why the events 21 
were not considered acute VTE events. In nearly two-thirds of all cases, the reason was that the 22 
 15 
encounter referred to a past history of VTE but there was no evidence of new, acute event 1 
(Table 4).   2 
 3 
Discussion 4 
Within a large, diverse, community-based sample of adults with a prior VTE receiving 5 
care within four integrated healthcare delivery systems, we found that ICD-9 diagnosis codes 6 
were not accurate in identifying recurrent VTE events. The validity of the relevant ICD-9 codes 7 
varied widely based on the type of VTE, diagnostic position of the relevant code, and encounter 8 
setting. In particular, diagnosis codes representing splanchnic thrombosis or thrombotic events 9 
at unspecified locations were very rarely related to true recurrent VTE events. Because of the 10 
low overall validity of administrative codes in identifying recurrent VTE, caution should be taken 11 
when interpreting findings of studies that rely solely on administrative codes to identify 12 
recurrent VTE events. Combination of ICD-9 codes with a new prescription for anticoagulants 13 
may result in improved accuracy to identify recurrent VTE diagnosed in the hospital or 14 
emergency department setting.   15 
Our study found that using administrative diagnosis codes for recurrent VTE events is 16 
even less accurate than when patients present with an first acute VTE episode.[13] This finding 17 
is in large part due to carry-over of past VTE codes in encounters (e.g. via patient history); 18 
although a substantial proportion of codes also represented initial suspicion for acute VTE that 19 
was subsequently ruled out after clinical evaluation. Our results are notable because while 20 
several studies have investigated the validity of ICD-9 codes for incident VTE,[7, 13, 19, 20] 21 
evidence on the validity of codes to identify recurrent VTE events is very limited. A previous 22 
 16 
study that validated ICD-9 codes to identify recurrent VTE events in claims data reported a PPV 1 
of 89%.[21] That study incorporated receipt of anticoagulation into their case identification 2 
algorithm and only assessed inpatient diagnoses of recurrent VTE events, along with including 3 
only 36 potential cases of recurrent VTE leading to limited precision and potential sampling 4 
bias.[21] In contrast, we performed manual review of medical records in more than 1,000 5 
encounters for potential recurrent VTE from both the inpatient and outpatient settings. It is 6 
also important to note that the issues that result in poor performance, in particular, carry-over 7 
from prior encounters, would not be addressed by improvements associated with the use of 8 
updated coding systems (e.g., ICD-10). 9 
Our results imply that findings and conclusions from research and policies that used 10 
administrative codes to define recurrent VTE events without confirmatory chart review are 11 
likely to be biased. Outcome misclassification tends to bias the results towards the null in cases 12 
of non-differential misclassification, while the direction of the bias is unknown when 13 
differential misclassification is present. Our findings suggest that previous large epidemiological 14 
studies that relied only on ICD-9 codes to define recurrent VTE events[22-25] would presumably 15 
overestimate true rates of recurrent VTE events due to associated high false-positive rates, in 16 
particular for studies that include ambulatory encounters.  17 
Prevention of VTE events is among the top priorities to improve patient safety in 18 
hospitals,[2, 5] and further research to create evidence with the aim of optimizing prevention 19 
and treatment strategies is urgently needed. While administrative databases include enormous 20 
repositories of health care-related data and facilitates comparatively efficient and more cost-21 
effective generation of new evidence by conducting observational studies on a large scale,[26] 22 
 17 
our results underline the need of ongoing efforts to ensure the accurate coding of diagnoses by 1 
physicians and coders, the importance of an adequate awareness of the performance of 2 
algorithms to identify health outcomes in order to correctly interpret and use research results 3 
that are based on administrative codes, and the necessity for further efforts to accurately 4 
define VTE outcomes in administrative databases. ICD-10 diagnosis codes have replaced 5 
relevant ICD-9 codes in October 2015 in the U.S, which have created more granularity in 6 
diagnosis, but a recent study shows that ICD-10 codes have similar poor accuracy for identifying 7 
thromboembolic complications of anticoagulation therapy including recurrent VTE events.[27] 8 
Our results showed that restricting inpatient diagnoses or ICD-9 codes in the primary position 9 
only does not sufficiently improve the PPV to a range that would be acceptable for outcomes 10 
research or quality improvement efforts. Combining new anticoagulant dispensing data from 11 
pharmacy databases with diagnostic codes of recurrent VTE did improve the overall PPV, 12 
resulting in a reasonable accuracy for identifying VTE recurrences if using ICD-9 codes in the 13 
primary position for hospital and emergency department encounters. However, given that only 14 
about a fourth (286 of 1036) of all hospital and emergency department encounters with 15 
potential recurrent VTE met the criteria for new anticoagulation prescriptions, there is a risk of 16 
missing true events.  ICD-9 codes for outpatient encounters failed to consistently distinguish 17 
recurrent VTE events from follow-up visits of patients anticoagulated for a previous VTE despite 18 
this improvement, reflecting the lower pre-test probability of VTE in the outpatient setting. 19 
Strategies to improve the validity of outcome diagnoses in health databases could include 20 
limiting codes to those associated with the “present on admission” flag, combination of 21 
administrative data and validated automated text processing methods with incorporation of 22 
 18 
additional laboratory and medication criteria or procedure codes, or the conduct of manual 1 
chart review to more accurately identify the diagnosis of interest.[28, 29] Quantitative bias 2 
analysis could represent another possibility to address potential misclassification resulting from 3 
imperfect validity of diagnoses.[30]   4 
The strength of our study was that we were able to assess the validity of recurrent VTE 5 
events by performing detailed manual review of medical records on a large number of 6 
encounters within administrative databases from a spectrum of healthcare delivery systems in 7 
the U.S. We used standardized criteria and considered all available medical data for manual 8 
review including admission, transfer and discharge records, emergency department and 9 
outpatient notes, and radiology reports, implying a high accuracy of our reported results for 10 
diagnosed recurrent VTE events. 11 
Our study has some limitations. As we did not manually screen charts without specific 12 
ICD-9 diagnosis codes suggestive of possible recurrent VTE, we were unable to determine 13 
sensitivity or specificity of ICD-9 codes to identify recurrent VTE events. We therefore are 14 
unable to draw firm conclusions on whether the use of administrative codes leads to an 15 
overestimation or underestimation of recurrent VTE events, particularly in specific 16 
subpopulations such as surgical patients.[7] However, given the low PPV, recurrent VTE events 17 
are likely overestimated. Our results cannot be directly applied to research using the new set of 18 
ICD-10 codes that were implemented starting in October 2015 nationally.[8] Our results may 19 
not be fully generalizable to all other health systems and datasets, although the four integrated 20 
healthcare delivery systems represent numerous hospitals and clinics serving a diverse 21 
population in the corresponding geographic areas. Finally, we were not able to identify the 22 
 19 
reasons for why codes suggesting recurrent VTE events were invalid for the 615 encounters 1 
that were only assessed using automated text processing, which may differ from the reasons 2 
identified by chart reviewers.  3 
 4 
Conclusions 5 
In conclusion, the validity of administrative ICD-9 codes to identify recurrent VTE events 6 
is insufficient, which is particularly relevant for pharmacoepidemiologic studies or outcomes 7 
research that solely rely on administrative codes to define recurrent VTE outcomes. Our 8 
findings suggest that the results of such studies should be interpreted with caution and that 9 
strategies to account for misclassification and further efforts to improve algorithms for 10 
ascertaining recurrent VTE events from medical records for research and quality improvement 11 
purposes are of utmost importance.  12 
  13 
 20 
Acknowledgements: None 1 





[1] C.E. Mahan, Regulatory, policy and quality update for venous thromboembolism and stroke 4 
in United States hospitals, Thromb Res 130(4) (2012) 586-90. 5 
[2] T.W. Wakefield, R.B. McLafferty, J.M. Lohr, J.A. Caprini, D.L. Gillespie, M.A. Passman, Call to 6 
action to prevent venous thromboembolism, J Vasc Surg 49(6) (2009) 1620-3. 7 
[3] E.A. Nutescu, C. Crivera, J.R. Schein, B.K. Bookhart, Incidence of hospital readmission in 8 
patients diagnosed with DVT and PE: clinical burden of recurrent events, Int J Clin Pract 69(3) 9 
(2015) 321-7. 10 
[4] The Centers for Medicare & Medicaid Services (CMS) and The Joint Commission, National 11 
Hospital Inpatient Quality Reporting Measures Specifications Manual, Release Notes Version: 12 
5.0. Available at: 13 
https://www.jointcommission.org/assets/1/6/IQRManualReleaseNotes_v5_01.PDF. Accessed 14 
July 18, 2019 (2015). 15 
[5] G. Maynard, Preventing hospital-associated venous thromboembolism: a guide for effective 16 
quality improvement, 2nd ed. Rockville, MD, Agency for Healthcare Research and Quality  17 
(2016. AHRQ Publication No. 16-0001-EF. Available at: 18 
https://www.ahrq.gov/sites/default/files/publications/files/vteguide.pdf, Accessed May 14, 19 
2018). 20 
[6] C. Mazzali, P. Duca, Use of administrative data in healthcare research, Internal & Emergency 21 
Medicine 10(4) (2015) 517-24. 22 
 22 
[7] L. Tamariz, T. Harkins, V. Nair, A systematic review of validated methods for identifying 1 
venous thromboembolism using administrative and claims data, Pharmacoepidemiol Drug Saf 2 
21 Suppl 1 (2012) 154-62. 3 
[8] Centers for Medicare and Medicaid Services, ICD-10. Available at: 4 
https://www.cms.gov/Medicare/Coding/ICD10/index.html,  (Accessed July 18, 2019). 5 
[9] M. Mayhew, L.L. DeBar, R.A. Deyo, R.D. Kerns, J.L. Goulet, C.A. Brandt, M. Von Korff, 6 
Development and Assessment of a Crosswalk Between ICD-9-CM and ICD-10-CM to Identify 7 
Patients with Common Pain Conditions, J Pain  (2019). 8 
[10] J.A. Columbo, R. Kang, S.W. Trooboff, K.S. Jahn, C.J. Martinez, K.O. Moore, A.M. Austin, N.E. 9 
Morden, C.G. Brooks, J.S. Skinner, P.P. Goodney, Validating Publicly Available Crosswalks for 10 
Translating ICD-9 to ICD-10 Diagnosis Codes for Cardiovascular Outcomes Research, Circulation: 11 
Cardiovascular Quality & Outcomes 11(10) (2018) e004782. 12 
[11] Patient-Centered Outcomes Research Institute, Comparing the Benefits and Harms of 13 
Medicines for Long-Term Treatment of Blood Clots -- The ALTERNATIVE Study. Available at: 14 
https://www.pcori.org/research-results/2016/comparing-benefits-and-harms-medicines-long-15 
term-treatment-blood-clots,  (Accessed July 18, 2019). 16 
[12] F.A. Spencer, D. Lessard, C. Emery, G. Reed, R.J. Goldberg, Venous thromboembolism in the 17 
outpatient setting, Arch Intern Med 167(14) (2007) 1471-5. 18 
[13] M.C. Fang, D. Fan, S.H. Sung, D.M. Witt, J.R. Schmelzer, S.R. Steinhubl, S.H. Yale, A.S. Go, 19 
Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous 20 
Thromboembolism: The CVRN VTE Study, Med Care 55(12) (2017) e137-e143. 21 
 23 
[14] U.S. Department of Health & Human Services, Office for Human Reserach Protections. 1 
Revised Common Rule. Available at: https://www.hhs.gov/ohrp/education-and-2 
outreach/revised-common-rule/revised-common-rule-q-and-a/index.html.,  (Accessed July 19, 3 
2019). 4 
[15] M.C. Fang, D. Fan, S.H. Sung, D.M. Witt, J.R. Schmelzer, M.S. Williams, S.H. Yale, C. 5 
Baumgartner, A.S. Go, Treatment and Outcomes of Acute Pulmonary Embolism and Deep 6 
Venous Thrombosis: The Cardiovascular Research Network Venous Thromboembolism (CVRN 7 
VTE) Study, Am J Med  (2019). 8 
[16] J. Perez Botero, W.D. Ormsby, A.A. Ashrani, R.D. McBane, 2nd, W.E. Wysokinski, M.M. 9 
Patnaik, B.R. Lewis, D.E. Grill, R.K. Pruthi, J.A. Heit, Do incident and recurrent venous 10 
thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden 11 
carriers? A retrospective cohort study, Eur J Intern Med 30 (2016) 77-81. 12 
[17] F.A. Spencer, C. Emery, D. Lessard, F. Anderson, S. Emani, J. Aragam, R.C. Becker, R.J. 13 
Goldberg, The Worcester Venous Thromboembolism study: a population-based study of the 14 
clinical epidemiology of venous thromboembolism, J Gen Intern Med 21(7) (2006) 722-7. 15 
[18] A.S. Go, D.J. Magid, B. Wells, S.H. Sung, A.E. Cassidy-Bushrow, R.T. Greenlee, R.D. Langer, 16 
T.A. Lieu, K.L. Margolis, F.A. Masoudi, C.J. McNeal, G.H. Murata, K.M. Newton, R. Novotny, K. 17 
Reynolds, D.W. Roblin, D.H. Smith, S. Vupputuri, R.E. White, J. Olson, J.S. Rumsfeld, J.H. Gurwitz, 18 
The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes 19 
research, Circulation: Cardiovascular Quality & Outcomes 1(2) (2008) 138-47. 20 
 24 
[19] R.H. White, M. Garcia, B. Sadeghi, D.J. Tancredi, P. Zrelak, J. Cuny, P. Sama, H. Gammon, S. 1 
Schmaltz, P.S. Romano, Evaluation of the predictive value of ICD-9-CM coded administrative 2 
data for venous thromboembolism in the United States, Thromb Res 126(1) (2010) 61-7. 3 
[20] F. Al-Ani, S. Shariff, L. Siqueira, A. Seyam, A. Lazo-Langner, Identifying venous 4 
thromboembolism and major bleeding in emergency room discharges using administrative 5 
data, Thromb Res 136(6) (2015) 1195-8. 6 
[21] V.J. Willey, M.F. Bullano, O. Hauch, M. Reynolds, G. Wygant, L. Hoffman, G. Mayzell, A.C. 7 
Spyropoulos, Management patterns and outcomes of patients with venous thromboembolism 8 
in the usual community practice setting, Clin Ther 26(7) (2004) 1149-59. 9 
[22] T.H. Toledano, D. Kondal, S.R. Kahn, V. Tagalakis, The occurrence of venous 10 
thromboembolism in cancer patients following major surgery, Thromb Res 131(1) (2013) e1-5. 11 
[23] M.B. Streiff, D. Milentijevic, K. McCrae, D. Yannicelli, J. Fortier, W.W. Nelson, F. Laliberte, C. 12 
Crivera, P. Lefebvre, J. Schein, A.A. Khorana, Effectiveness and safety of anticoagulants for the 13 
treatment of venous thromboembolism in patients with cancer, Am J Hematol 93(5) (2018) 14 
664-671. 15 
[24] C.I. Coleman, A.G.G. Turpie, T.J. Bunz, J. Beyer-Westendorf, Effectiveness and Safety of 16 
Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism, Am J Med  17 
(2018). 18 
[25] C.I. Coleman, T.J. Bunz, A.G.G. Turpie, Effectiveness and safety of rivaroxaban versus 19 
warfarin for treatment and prevention of recurrence of venous thromboembolism, Thrombosis 20 
& Haemostasis 117(10) (2017) 1841-1847. 21 
 25 
[26] N. Gavrielov-Yusim, M. Friger, Use of administrative medical databases in population-based 1 
research, Journal of Epidemiology & Community Health 68(3) (2014) 283-7. 2 
[27] K. Lawrence, C. Joos, A.E. Jones, S.A. Johnson, D.M. Witt, Assessing the accuracy of ICD-10 3 
codes for identifying acute thromboembolic events among patients receiving anticoagulation 4 
therapy, Journal of Thrombosis & Thrombolysis 48(2) (2019) 181-186. 5 
[28] G.S. Alotaibi, C. Wu, A. Senthilselvan, M.S. McMurtry, The validity of ICD codes coupled 6 
with imaging procedure codes for identifying acute venous thromboembolism using 7 
administrative data, Vasc Med 20(4) (2015) 364-8. 8 
[29] K.M. Sanfilippo, T.F. Wang, B.F. Gage, W. Liu, K.R. Carson, Improving accuracy of 9 
International Classification of Diseases codes for venous thromboembolism in administrative 10 
data, Thromb Res 135(4) (2015) 616-20. 11 
[30] T.L. Lash, M.P. Fox, R.F. MacLehose, G. Maldonado, L.C. McCandless, S. Greenland, Good 12 
practices for quantitative bias analysis, Int J Epidemiol 43(6) (2014) 1969-85. 13 
 14 
